Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

China flag China · Delayed Price · Currency is CNY
22.35
+0.09 (0.40%)
Apr 29, 2025, 1:45 PM CST
-9.92%
Market Cap 22.62B
Revenue (ttm) 5.85B
Net Income (ttm) 1.18B
Shares Out 1.02B
EPS (ttm) 1.17
PE Ratio 19.02
Forward PE 15.25
Dividend 0.36 (1.62%)
Ex-Dividend Date May 15, 2024
Volume 3,691,800
Average Volume 10,159,206
Open 22.68
Previous Close 22.26
Day's Range 22.15 - 22.68
52-Week Range 20.36 - 29.98
Beta 0.01
RSI 50.69
Earnings Date Jul 31, 2025

About SHE:002262

Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. It’s product portfolio includes Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc.; and Iptakalim, an anti-hypertension drug. The company’s products are used for treatment of anesthesiology, psychiatry and neurology, as well as APIs. Jiangsu Nhwa Pharmaceutical Co., LTD was founded in 1978 and is headquartered in Xuzhou, China. [Read more]

Sector Healthcare
Founded 1978
Employees 5,923
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002262
Full Company Profile

Financial Performance

In 2024, SHE:002262's revenue was 5.70 billion, an increase of 13.01% compared to the previous year's 5.04 billion. Earnings were 1.14 billion, an increase of 10.28%.

Financial Statements

News

There is no news available yet.